Jazz Pharmaceuticals plc (JAZZ)
- Previous Close
98.41 - Open
98.61 - Bid 97.97 x 200
- Ask 98.59 x 200
- Day's Range
97.69 - 99.98 - 52 Week Range
95.49 - 148.06 - Volume
743,438 - Avg. Volume
1,317,817 - Market Cap (intraday)
6.057B - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
13.35 - EPS (TTM)
7.36 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
184.00
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
www.jazzpharma.comRecent News: JAZZ
View More
Performance Overview: JAZZ
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JAZZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JAZZ
View MoreValuation Measures
Market Cap
6.07B
Enterprise Value
8.91B
Trailing P/E
13.37
Forward P/E
5.94
PEG Ratio (5yr expected)
0.43
Price/Sales (ttm)
1.59
Price/Book (mrq)
1.45
Enterprise Value/Revenue
2.19
Enterprise Value/EBITDA
7.13
Financial Highlights
Profitability and Income Statement
Profit Margin
11.86%
Return on Assets (ttm)
3.99%
Return on Equity (ttm)
12.25%
Revenue (ttm)
4.06B
Net Income Avi to Common (ttm)
482.2M
Diluted EPS (ttm)
7.36
Balance Sheet and Cash Flow
Total Cash (mrq)
2.57B
Total Debt/Equity (mrq)
129.50%
Levered Free Cash Flow (ttm)
1.53B
Research Analysis: JAZZ
View MoreResearch Reports: JAZZ
View MoreJazz Earnings: Strong Demand for Epidiolex and Xywav Drive Growth; Shares Very Undervalued
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
RatingPrice TargetJazz Earnings: Strong Uptake of Xywav and Epidiolex Drive Sales; Shares Undervalued
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
RatingPrice TargetLowering target price to $122.00
JAZZ PHARMACEUTICALS PLC has an Investment Rating of BUY; a target price of $122.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetJazz Earnings: Strong Uptake of Xywav and Epidiolex Drive Sales; Shares Undervalued
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
RatingPrice Target